ATE295421T1 - Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell- immunantwort gegen antigen - Google Patents

Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell- immunantwort gegen antigen

Info

Publication number
ATE295421T1
ATE295421T1 AT00960857T AT00960857T ATE295421T1 AT E295421 T1 ATE295421 T1 AT E295421T1 AT 00960857 T AT00960857 T AT 00960857T AT 00960857 T AT00960857 T AT 00960857T AT E295421 T1 ATE295421 T1 AT E295421T1
Authority
AT
Austria
Prior art keywords
antigen
replication
immune response
adenoviral vector
medication
Prior art date
Application number
AT00960857T
Other languages
German (de)
English (en)
Inventor
Joerg Schneider
Sarah Catherine Gilbert
Carolyn Mary Hannan
Adrian Vivian Sinton Hill
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE295421(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE295421T1 publication Critical patent/ATE295421T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00960857T 1999-09-21 2000-09-20 Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell- immunantwort gegen antigen ATE295421T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
PCT/GB2000/003601 WO2001021201A2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen

Publications (1)

Publication Number Publication Date
ATE295421T1 true ATE295421T1 (de) 2005-05-15

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00960857T ATE295421T1 (de) 1999-09-21 2000-09-20 Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell- immunantwort gegen antigen

Country Status (12)

Country Link
EP (2) EP1612269A1 (enExample)
JP (1) JP2003509470A (enExample)
CN (1) CN1391609A (enExample)
AT (1) ATE295421T1 (enExample)
AU (1) AU762894B2 (enExample)
BR (1) BR0014138A (enExample)
CA (1) CA2384806A1 (enExample)
DE (1) DE60020136T2 (enExample)
DK (1) DK1214416T3 (enExample)
ES (1) ES2241653T3 (enExample)
GB (1) GB9922361D0 (enExample)
WO (1) WO2001021201A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
JP4654026B2 (ja) * 2002-05-20 2011-03-16 独立行政法人科学技術振興機構 Ｂｃｇワクチンとその利用
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
JP5646851B2 (ja) * 2006-11-17 2014-12-24 ジェネトロニクス，インコーポレイティド エレクトロポレーション支援ワクチン投与及び追加投与を用いた免疫応答の増強方法
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
CA2699465C (en) * 2007-09-14 2017-11-28 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
MX380483B (es) * 2012-10-28 2025-03-12 Bavarian Nordic As Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.
EP3595705A1 (en) 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Method
MX2022004484A (es) * 2019-10-16 2022-07-19 Cancer Research Tech Ltd Vector para el tratamiento de cancer.
EP4444347A1 (en) 2021-12-07 2024-10-16 Barinthus Biotherapeutics (UK) Limited Vaccine boost methods and compositions
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine

Also Published As

Publication number Publication date
BR0014138A (pt) 2002-05-21
WO2001021201A3 (en) 2001-10-18
DK1214416T3 (da) 2005-08-29
DE60020136D1 (de) 2005-06-16
DE60020136T2 (de) 2006-02-23
CA2384806A1 (en) 2001-03-29
JP2003509470A (ja) 2003-03-11
EP1612269A1 (en) 2006-01-04
EP1214416A2 (en) 2002-06-19
AU7302400A (en) 2001-04-24
EP1214416B1 (en) 2005-05-11
AU762894B2 (en) 2003-07-10
CN1391609A (zh) 2003-01-15
GB9922361D0 (en) 1999-11-24
ES2241653T3 (es) 2005-11-01
WO2001021201A2 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
DE60020136D1 (de) Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell-immunantwort gegen antigen
Liu et al. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
DE69434820D1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
DE69229476D1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
DE69836588D1 (de) Tuberkulose impfstoff
EP2204179A3 (en) Modified Vaccinia Virus Ankara for the vaccination of neonates
ATE237682T1 (de) Universale spenderzellen
WO2000053767A3 (en) Nucleic acid respiratory syncytial virus vaccines
DE59712852D1 (de) Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
EP1932915A3 (en) Materials and methods relating to improved vaccination strategies
DE69635472D1 (de) Impfstoff gegen Geflügelkokzidose
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
DE69432137D1 (de) Impfstoff gegen Geflügelkokzidose
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
DK1272652T3 (da) Herpesvirus til immunmodulation
ATE201446T1 (de) Impfstoff gegen geflügelkokzidose
BRPI0209416A8 (pt) novos vetores de expressão e uso dos mesmos
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
WO2003075849A3 (en) Composition and method for enhancing immune response
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
DE60033679D1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1214416

Country of ref document: EP

RZN Patent revoked